Last reviewed · How we verify
Vancomycin oral liquid
Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of Clostridioides difficile infection, Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
At a glance
| Generic name | Vancomycin oral liquid |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | glycopeptide antibiotic |
| Target | D-alanyl-D-alanine terminus of cell wall precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This action prevents the formation of a functional cell wall, ultimately leading to bacterial cell lysis and death. Vancomycin is a glycopeptide antibiotic that has been used to treat various bacterial infections.
Approved indications
- Treatment of Clostridioides difficile infection
- Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Combination Study of Antibiotics With Enzalutamide (PROMIZE) (PHASE1, PHASE2)
- Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients (PHASE2, PHASE3)
- Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC (EARLY_PHASE1)
- A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (PHASE3)
- Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders (PHASE2)
- Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin oral liquid CI brief — competitive landscape report
- Vancomycin oral liquid updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI